Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Adaptimmune Therapeutics plc
ADAP
Healthcare
Biotechnology
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include...
afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Company’s most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ADAP)
New Post
View:
Posts & Comments
Threaded Posts
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 12, 2024 10:47am
Medical Tech and Biotech Stocks to Watch and the Treatments
NEWS: $ADAP Medical Tech and Biotech Stocks to Watch and the Treatments for Solid Tumors2024-08-12 10:10:00 ET August 12, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 05, 2024 10:01pm
Adaptimmune to Report Q2 2024 Financial and Business Updates
Just In: $ADAP Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 5, 2024
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 21, 2024 4:15pm
Adaptimmune to Report Q4 and Full Year 2023 Financial and Bu
Breaking News: $ADAP Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp
...more
(8)
•••
hoffbag
X
View Profile
View Bullboard History
Post by
hoffbag
on Aug 24, 2022 6:05pm
Some giddy yapping here....
Will see how they go. Expensive, but helpful treatment today.....maybe a future here.
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Learn How this Company is Disrupting Point-of-Care Testing
Why Dozens of Pro Athletes are Paying Attention to this Product
Do you want to stay ahead of the markets? See how DealRoom can help.
Debt-Free Cannabis Company Set for Next Stage of Growth
Growth Rocket 2025 – Why dynaCERT is in the Spotlight